Global RNA Medicine Market

RNA Medicine Comprehensive Study by Type (RNA Interference, ASO, MiRNA, Nucleic Acid Aptamers, Others), Application (Cancer, Diabetes, Genetic Disorder, Cardiovascular Diseases, Others), End User (Academic & Research Institutes, Biotechnology Industries, Pharmaceutical Industries, Hospitals, Clinics, Others), Technology (Nucleic Acid Drug Delivery, Aptamer Drug Delivery, Nanoparticle Drug Delivery, Others) Players and Region - Global Market Outlook to 2027

RNA Medicine Market by XX Submarkets | Forecast Years 2023-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
RNA Medicine Market Scope
The factors driving the market expansion are an increase in chronic diseases and disorders as well as the popularity of personalised treatments. Drug administration via ribonucleic acid interference (RNAi) is a therapeutic approach to track changes in gene expression. The most common ways to administer RNAi medications include intravenous, intradermal, intraperitoneal, and topical routes of administration. It makes use of pulmonary, nucleic acid, aptamer, and nanoparticle drug delivery techniques. These technologies are also employed in the study of eukaryotic gene functions and the creation of therapeutic methods for gene silencing. In order to treat infectious diseases, long-term metabolic problems, cardiovascular, neurological, urological, oncological, and ophthalmological disorders, RNAi drug delivery is frequently employed.

AttributesDetails
Study Period2017-2027
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledPfizer (United States), Sarepta Therapeutics (United States), Quark (United States), RXi (United Kingdom), Senesco (United States), Roche (‎Switzerland), Ionis Pharmaceuticals (United States), Moderna (Europe), Sanofi-Aventis (France), Abbott Laboratories (United States), BioNTech (Germany), Tekmira (Canada), Alnylam Pharmaceuticals (United States), Arrowhead Pharmaceuticals (United States) and Benitec Biopharma (United States)
CAGR%


The market for the RNA Medicine is highly competitive and dominated by few key player. The market has a vendor landscape that is extremely competitive. A number of businesses are also taking part in significant mergers and acquisitions as part of crucial plans to increase their market share globally. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global RNA Medicine market throughout the predicted period.

Pfizer (United States), Sarepta Therapeutics (United States), Quark (United States), RXi (United Kingdom), Senesco (United States), Roche (‎Switzerland), Ionis Pharmaceuticals (United States), Moderna (Europe), Sanofi-Aventis (France), Abbott Laboratories (United States), BioNTech (Germany), Tekmira (Canada), Alnylam Pharmaceuticals (United States), Arrowhead Pharmaceuticals (United States) and Benitec Biopharma (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Calimmune Inc (United States), Dicerna (United States), Gradalis (United States), Silence Therapeutics (United Kingdom) and Silenseed (Israel).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global RNA Medicine market by Type , by Application (Cancer, Diabetes, Genetic Disorder, Cardiovascular Diseases and Others) and Region with country level break-up.

On the basis of geography, the market of RNA Medicine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2022.

Market Leaders and their expansionary development strategies
On June 2021, The Tampa, Florida-based, privately held Trasir Therapeutics, Inc. ("Trasir"), a pioneer in extrahepatic oligonucleotide delivery, has been acquired by Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company committed to developing therapeutics that address significant unmet medical needs in neurotology, rhinology, allergy, and CNS disorders and On August 2021, Sanofi will acquire Translate Bio, advancing the use of mRNA technology in the development of vaccines and treatments. The acquisition is intended to expedite the construction of Sanofi's previously announced mRNA Center of Excellence, accelerate the development of currently licenced vaccination programmes currently offered by Sanofi, and maybe open the door to other therapeutic areas
On September 2022, the biotechnology industry's R&D cloud, Benchling, today unveiled the first comprehensive set of capabilities for designing, modelling, and researching both naturally occurring and chemically altered RNA in a single system. The development of RNA therapies is a growing area of interest for the biopharmaceutical sector, and Benchling's new RNA solution is the first product specifically designed to assist R&D organisations in accelerating the delivery of drug candidates


Influencing Trend:
Rising demand for personalized medicine boost the market growth

Market Growth Drivers:
Increase in chronic diseases and disorders drives the market growth and Rise in the geriatric population propels the market forward

Challenges:
Challenges to drug delivery limit the market's expansion and Lack of skilled work force hampers the market growth

Restraints:
Threats of failure and expensive research costs limit market expansion

Opportunities:
Various technological developments, such as the creation of creative synthetic delivery systems and bio-vectors, generate abundant market expansion potential

Key Target Audience
New Entrants and Investors, Laboratories, Hospitals, Diagnostic Centres, Clinics, Research Institutes, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

Report Objectives / Segmentation Covered

By Type
  • RNA Interference
  • ASO
  • miRNA
  • Nucleic Acid Aptamers
  • Others
By Application
  • Cancer
  • Diabetes
  • Genetic Disorder
  • Cardiovascular Diseases
  • Others
By End User
  • Academic & Research Institutes
  • Biotechnology Industries
  • Pharmaceutical Industries
  • Hospitals
  • Clinics
  • Others

By Technology
  • Nucleic Acid Drug Delivery
  • Aptamer Drug Delivery
  • Nanoparticle Drug Delivery
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in chronic diseases and disorders drives the market growth
      • 3.2.2. Rise in the geriatric population propels the market forward
    • 3.3. Market Challenges
      • 3.3.1. Challenges to drug delivery limit the market's expansion
      • 3.3.2. Lack of skilled work force hampers the market growth
    • 3.4. Market Trends
      • 3.4.1. Rising demand for personalized medicine boost the market growth
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global RNA Medicine, by Type, Application, End User , Technology and Region (value and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global RNA Medicine (Value)
      • 5.2.1. Global RNA Medicine by: Type (Value)
        • 5.2.1.1. RNA Interference
        • 5.2.1.2. ASO
        • 5.2.1.3. MiRNA
        • 5.2.1.4. Nucleic Acid Aptamers
        • 5.2.1.5. Others
      • 5.2.2. Global RNA Medicine by: Application (Value)
        • 5.2.2.1. Cancer
        • 5.2.2.2. Diabetes
        • 5.2.2.3. Genetic Disorder
        • 5.2.2.4. Cardiovascular Diseases
        • 5.2.2.5. Others
      • 5.2.3. Global RNA Medicine Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Australia
          • 5.2.3.2.6. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global RNA Medicine (Price)
      • 5.3.1. Global RNA Medicine by: Type (Price)
  • 6. RNA Medicine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sarepta Therapeutics (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Quark (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. RXi (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Senesco (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Roche (‎Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Ionis Pharmaceuticals (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Moderna (Europe)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sanofi-Aventis (France)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Abbott Laboratories (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. BioNTech (Germany)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Tekmira (Canada)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Alnylam Pharmaceuticals (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Arrowhead Pharmaceuticals (United States)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Benitec Biopharma (United States)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
  • 7. Global RNA Medicine Sale, by Type, Application, End User , Technology and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global RNA Medicine (Value)
      • 7.2.1. Global RNA Medicine by: Type (Value)
        • 7.2.1.1. RNA Interference
        • 7.2.1.2. ASO
        • 7.2.1.3. MiRNA
        • 7.2.1.4. Nucleic Acid Aptamers
        • 7.2.1.5. Others
      • 7.2.2. Global RNA Medicine by: Application (Value)
        • 7.2.2.1. Cancer
        • 7.2.2.2. Diabetes
        • 7.2.2.3. Genetic Disorder
        • 7.2.2.4. Cardiovascular Diseases
        • 7.2.2.5. Others
      • 7.2.3. Global RNA Medicine Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Australia
          • 7.2.3.2.6. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global RNA Medicine (Price)
      • 7.3.1. Global RNA Medicine by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. RNA Medicine: by Type(USD Million)
  • Table 2. RNA Medicine RNA Interference , by Region USD Million (2017-2022)
  • Table 3. RNA Medicine ASO , by Region USD Million (2017-2022)
  • Table 4. RNA Medicine MiRNA , by Region USD Million (2017-2022)
  • Table 5. RNA Medicine Nucleic Acid Aptamers , by Region USD Million (2017-2022)
  • Table 6. RNA Medicine Others , by Region USD Million (2017-2022)
  • Table 7. RNA Medicine: by Application(USD Million)
  • Table 8. RNA Medicine Cancer , by Region USD Million (2017-2022)
  • Table 9. RNA Medicine Diabetes , by Region USD Million (2017-2022)
  • Table 10. RNA Medicine Genetic Disorder , by Region USD Million (2017-2022)
  • Table 11. RNA Medicine Cardiovascular Diseases , by Region USD Million (2017-2022)
  • Table 12. RNA Medicine Others , by Region USD Million (2017-2022)
  • Table 13. South America RNA Medicine, by Country USD Million (2017-2022)
  • Table 14. South America RNA Medicine, by Type USD Million (2017-2022)
  • Table 15. South America RNA Medicine, by Application USD Million (2017-2022)
  • Table 16. South America RNA Medicine, by End User USD Million (2017-2022)
  • Table 17. South America RNA Medicine, by Technology USD Million (2017-2022)
  • Table 18. Brazil RNA Medicine, by Type USD Million (2017-2022)
  • Table 19. Brazil RNA Medicine, by Application USD Million (2017-2022)
  • Table 20. Brazil RNA Medicine, by End User USD Million (2017-2022)
  • Table 21. Brazil RNA Medicine, by Technology USD Million (2017-2022)
  • Table 22. Argentina RNA Medicine, by Type USD Million (2017-2022)
  • Table 23. Argentina RNA Medicine, by Application USD Million (2017-2022)
  • Table 24. Argentina RNA Medicine, by End User USD Million (2017-2022)
  • Table 25. Argentina RNA Medicine, by Technology USD Million (2017-2022)
  • Table 26. Rest of South America RNA Medicine, by Type USD Million (2017-2022)
  • Table 27. Rest of South America RNA Medicine, by Application USD Million (2017-2022)
  • Table 28. Rest of South America RNA Medicine, by End User USD Million (2017-2022)
  • Table 29. Rest of South America RNA Medicine, by Technology USD Million (2017-2022)
  • Table 30. Asia Pacific RNA Medicine, by Country USD Million (2017-2022)
  • Table 31. Asia Pacific RNA Medicine, by Type USD Million (2017-2022)
  • Table 32. Asia Pacific RNA Medicine, by Application USD Million (2017-2022)
  • Table 33. Asia Pacific RNA Medicine, by End User USD Million (2017-2022)
  • Table 34. Asia Pacific RNA Medicine, by Technology USD Million (2017-2022)
  • Table 35. China RNA Medicine, by Type USD Million (2017-2022)
  • Table 36. China RNA Medicine, by Application USD Million (2017-2022)
  • Table 37. China RNA Medicine, by End User USD Million (2017-2022)
  • Table 38. China RNA Medicine, by Technology USD Million (2017-2022)
  • Table 39. Japan RNA Medicine, by Type USD Million (2017-2022)
  • Table 40. Japan RNA Medicine, by Application USD Million (2017-2022)
  • Table 41. Japan RNA Medicine, by End User USD Million (2017-2022)
  • Table 42. Japan RNA Medicine, by Technology USD Million (2017-2022)
  • Table 43. India RNA Medicine, by Type USD Million (2017-2022)
  • Table 44. India RNA Medicine, by Application USD Million (2017-2022)
  • Table 45. India RNA Medicine, by End User USD Million (2017-2022)
  • Table 46. India RNA Medicine, by Technology USD Million (2017-2022)
  • Table 47. South Korea RNA Medicine, by Type USD Million (2017-2022)
  • Table 48. South Korea RNA Medicine, by Application USD Million (2017-2022)
  • Table 49. South Korea RNA Medicine, by End User USD Million (2017-2022)
  • Table 50. South Korea RNA Medicine, by Technology USD Million (2017-2022)
  • Table 51. Australia RNA Medicine, by Type USD Million (2017-2022)
  • Table 52. Australia RNA Medicine, by Application USD Million (2017-2022)
  • Table 53. Australia RNA Medicine, by End User USD Million (2017-2022)
  • Table 54. Australia RNA Medicine, by Technology USD Million (2017-2022)
  • Table 55. Rest of Asia-Pacific RNA Medicine, by Type USD Million (2017-2022)
  • Table 56. Rest of Asia-Pacific RNA Medicine, by Application USD Million (2017-2022)
  • Table 57. Rest of Asia-Pacific RNA Medicine, by End User USD Million (2017-2022)
  • Table 58. Rest of Asia-Pacific RNA Medicine, by Technology USD Million (2017-2022)
  • Table 59. Europe RNA Medicine, by Country USD Million (2017-2022)
  • Table 60. Europe RNA Medicine, by Type USD Million (2017-2022)
  • Table 61. Europe RNA Medicine, by Application USD Million (2017-2022)
  • Table 62. Europe RNA Medicine, by End User USD Million (2017-2022)
  • Table 63. Europe RNA Medicine, by Technology USD Million (2017-2022)
  • Table 64. Germany RNA Medicine, by Type USD Million (2017-2022)
  • Table 65. Germany RNA Medicine, by Application USD Million (2017-2022)
  • Table 66. Germany RNA Medicine, by End User USD Million (2017-2022)
  • Table 67. Germany RNA Medicine, by Technology USD Million (2017-2022)
  • Table 68. France RNA Medicine, by Type USD Million (2017-2022)
  • Table 69. France RNA Medicine, by Application USD Million (2017-2022)
  • Table 70. France RNA Medicine, by End User USD Million (2017-2022)
  • Table 71. France RNA Medicine, by Technology USD Million (2017-2022)
  • Table 72. Italy RNA Medicine, by Type USD Million (2017-2022)
  • Table 73. Italy RNA Medicine, by Application USD Million (2017-2022)
  • Table 74. Italy RNA Medicine, by End User USD Million (2017-2022)
  • Table 75. Italy RNA Medicine, by Technology USD Million (2017-2022)
  • Table 76. United Kingdom RNA Medicine, by Type USD Million (2017-2022)
  • Table 77. United Kingdom RNA Medicine, by Application USD Million (2017-2022)
  • Table 78. United Kingdom RNA Medicine, by End User USD Million (2017-2022)
  • Table 79. United Kingdom RNA Medicine, by Technology USD Million (2017-2022)
  • Table 80. Netherlands RNA Medicine, by Type USD Million (2017-2022)
  • Table 81. Netherlands RNA Medicine, by Application USD Million (2017-2022)
  • Table 82. Netherlands RNA Medicine, by End User USD Million (2017-2022)
  • Table 83. Netherlands RNA Medicine, by Technology USD Million (2017-2022)
  • Table 84. Rest of Europe RNA Medicine, by Type USD Million (2017-2022)
  • Table 85. Rest of Europe RNA Medicine, by Application USD Million (2017-2022)
  • Table 86. Rest of Europe RNA Medicine, by End User USD Million (2017-2022)
  • Table 87. Rest of Europe RNA Medicine, by Technology USD Million (2017-2022)
  • Table 88. MEA RNA Medicine, by Country USD Million (2017-2022)
  • Table 89. MEA RNA Medicine, by Type USD Million (2017-2022)
  • Table 90. MEA RNA Medicine, by Application USD Million (2017-2022)
  • Table 91. MEA RNA Medicine, by End User USD Million (2017-2022)
  • Table 92. MEA RNA Medicine, by Technology USD Million (2017-2022)
  • Table 93. Middle East RNA Medicine, by Type USD Million (2017-2022)
  • Table 94. Middle East RNA Medicine, by Application USD Million (2017-2022)
  • Table 95. Middle East RNA Medicine, by End User USD Million (2017-2022)
  • Table 96. Middle East RNA Medicine, by Technology USD Million (2017-2022)
  • Table 97. Africa RNA Medicine, by Type USD Million (2017-2022)
  • Table 98. Africa RNA Medicine, by Application USD Million (2017-2022)
  • Table 99. Africa RNA Medicine, by End User USD Million (2017-2022)
  • Table 100. Africa RNA Medicine, by Technology USD Million (2017-2022)
  • Table 101. North America RNA Medicine, by Country USD Million (2017-2022)
  • Table 102. North America RNA Medicine, by Type USD Million (2017-2022)
  • Table 103. North America RNA Medicine, by Application USD Million (2017-2022)
  • Table 104. North America RNA Medicine, by End User USD Million (2017-2022)
  • Table 105. North America RNA Medicine, by Technology USD Million (2017-2022)
  • Table 106. United States RNA Medicine, by Type USD Million (2017-2022)
  • Table 107. United States RNA Medicine, by Application USD Million (2017-2022)
  • Table 108. United States RNA Medicine, by End User USD Million (2017-2022)
  • Table 109. United States RNA Medicine, by Technology USD Million (2017-2022)
  • Table 110. Canada RNA Medicine, by Type USD Million (2017-2022)
  • Table 111. Canada RNA Medicine, by Application USD Million (2017-2022)
  • Table 112. Canada RNA Medicine, by End User USD Million (2017-2022)
  • Table 113. Canada RNA Medicine, by Technology USD Million (2017-2022)
  • Table 114. Mexico RNA Medicine, by Type USD Million (2017-2022)
  • Table 115. Mexico RNA Medicine, by Application USD Million (2017-2022)
  • Table 116. Mexico RNA Medicine, by End User USD Million (2017-2022)
  • Table 117. Mexico RNA Medicine, by Technology USD Million (2017-2022)
  • Table 118. RNA Medicine: by Type(USD/Units)
  • Table 119. Company Basic Information, Sales Area and Its Competitors
  • Table 120. Company Basic Information, Sales Area and Its Competitors
  • Table 121. Company Basic Information, Sales Area and Its Competitors
  • Table 122. Company Basic Information, Sales Area and Its Competitors
  • Table 123. Company Basic Information, Sales Area and Its Competitors
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. RNA Medicine: by Type(USD Million)
  • Table 135. RNA Medicine RNA Interference , by Region USD Million (2022-2027)
  • Table 136. RNA Medicine ASO , by Region USD Million (2022-2027)
  • Table 137. RNA Medicine MiRNA , by Region USD Million (2022-2027)
  • Table 138. RNA Medicine Nucleic Acid Aptamers , by Region USD Million (2022-2027)
  • Table 139. RNA Medicine Others , by Region USD Million (2022-2027)
  • Table 140. RNA Medicine: by Application(USD Million)
  • Table 141. RNA Medicine Cancer , by Region USD Million (2022-2027)
  • Table 142. RNA Medicine Diabetes , by Region USD Million (2022-2027)
  • Table 143. RNA Medicine Genetic Disorder , by Region USD Million (2022-2027)
  • Table 144. RNA Medicine Cardiovascular Diseases , by Region USD Million (2022-2027)
  • Table 145. RNA Medicine Others , by Region USD Million (2022-2027)
  • Table 146. South America RNA Medicine, by Country USD Million (2022-2027)
  • Table 147. South America RNA Medicine, by Type USD Million (2022-2027)
  • Table 148. South America RNA Medicine, by Application USD Million (2022-2027)
  • Table 149. South America RNA Medicine, by End User USD Million (2022-2027)
  • Table 150. South America RNA Medicine, by Technology USD Million (2022-2027)
  • Table 151. Brazil RNA Medicine, by Type USD Million (2022-2027)
  • Table 152. Brazil RNA Medicine, by Application USD Million (2022-2027)
  • Table 153. Brazil RNA Medicine, by End User USD Million (2022-2027)
  • Table 154. Brazil RNA Medicine, by Technology USD Million (2022-2027)
  • Table 155. Argentina RNA Medicine, by Type USD Million (2022-2027)
  • Table 156. Argentina RNA Medicine, by Application USD Million (2022-2027)
  • Table 157. Argentina RNA Medicine, by End User USD Million (2022-2027)
  • Table 158. Argentina RNA Medicine, by Technology USD Million (2022-2027)
  • Table 159. Rest of South America RNA Medicine, by Type USD Million (2022-2027)
  • Table 160. Rest of South America RNA Medicine, by Application USD Million (2022-2027)
  • Table 161. Rest of South America RNA Medicine, by End User USD Million (2022-2027)
  • Table 162. Rest of South America RNA Medicine, by Technology USD Million (2022-2027)
  • Table 163. Asia Pacific RNA Medicine, by Country USD Million (2022-2027)
  • Table 164. Asia Pacific RNA Medicine, by Type USD Million (2022-2027)
  • Table 165. Asia Pacific RNA Medicine, by Application USD Million (2022-2027)
  • Table 166. Asia Pacific RNA Medicine, by End User USD Million (2022-2027)
  • Table 167. Asia Pacific RNA Medicine, by Technology USD Million (2022-2027)
  • Table 168. China RNA Medicine, by Type USD Million (2022-2027)
  • Table 169. China RNA Medicine, by Application USD Million (2022-2027)
  • Table 170. China RNA Medicine, by End User USD Million (2022-2027)
  • Table 171. China RNA Medicine, by Technology USD Million (2022-2027)
  • Table 172. Japan RNA Medicine, by Type USD Million (2022-2027)
  • Table 173. Japan RNA Medicine, by Application USD Million (2022-2027)
  • Table 174. Japan RNA Medicine, by End User USD Million (2022-2027)
  • Table 175. Japan RNA Medicine, by Technology USD Million (2022-2027)
  • Table 176. India RNA Medicine, by Type USD Million (2022-2027)
  • Table 177. India RNA Medicine, by Application USD Million (2022-2027)
  • Table 178. India RNA Medicine, by End User USD Million (2022-2027)
  • Table 179. India RNA Medicine, by Technology USD Million (2022-2027)
  • Table 180. South Korea RNA Medicine, by Type USD Million (2022-2027)
  • Table 181. South Korea RNA Medicine, by Application USD Million (2022-2027)
  • Table 182. South Korea RNA Medicine, by End User USD Million (2022-2027)
  • Table 183. South Korea RNA Medicine, by Technology USD Million (2022-2027)
  • Table 184. Australia RNA Medicine, by Type USD Million (2022-2027)
  • Table 185. Australia RNA Medicine, by Application USD Million (2022-2027)
  • Table 186. Australia RNA Medicine, by End User USD Million (2022-2027)
  • Table 187. Australia RNA Medicine, by Technology USD Million (2022-2027)
  • Table 188. Rest of Asia-Pacific RNA Medicine, by Type USD Million (2022-2027)
  • Table 189. Rest of Asia-Pacific RNA Medicine, by Application USD Million (2022-2027)
  • Table 190. Rest of Asia-Pacific RNA Medicine, by End User USD Million (2022-2027)
  • Table 191. Rest of Asia-Pacific RNA Medicine, by Technology USD Million (2022-2027)
  • Table 192. Europe RNA Medicine, by Country USD Million (2022-2027)
  • Table 193. Europe RNA Medicine, by Type USD Million (2022-2027)
  • Table 194. Europe RNA Medicine, by Application USD Million (2022-2027)
  • Table 195. Europe RNA Medicine, by End User USD Million (2022-2027)
  • Table 196. Europe RNA Medicine, by Technology USD Million (2022-2027)
  • Table 197. Germany RNA Medicine, by Type USD Million (2022-2027)
  • Table 198. Germany RNA Medicine, by Application USD Million (2022-2027)
  • Table 199. Germany RNA Medicine, by End User USD Million (2022-2027)
  • Table 200. Germany RNA Medicine, by Technology USD Million (2022-2027)
  • Table 201. France RNA Medicine, by Type USD Million (2022-2027)
  • Table 202. France RNA Medicine, by Application USD Million (2022-2027)
  • Table 203. France RNA Medicine, by End User USD Million (2022-2027)
  • Table 204. France RNA Medicine, by Technology USD Million (2022-2027)
  • Table 205. Italy RNA Medicine, by Type USD Million (2022-2027)
  • Table 206. Italy RNA Medicine, by Application USD Million (2022-2027)
  • Table 207. Italy RNA Medicine, by End User USD Million (2022-2027)
  • Table 208. Italy RNA Medicine, by Technology USD Million (2022-2027)
  • Table 209. United Kingdom RNA Medicine, by Type USD Million (2022-2027)
  • Table 210. United Kingdom RNA Medicine, by Application USD Million (2022-2027)
  • Table 211. United Kingdom RNA Medicine, by End User USD Million (2022-2027)
  • Table 212. United Kingdom RNA Medicine, by Technology USD Million (2022-2027)
  • Table 213. Netherlands RNA Medicine, by Type USD Million (2022-2027)
  • Table 214. Netherlands RNA Medicine, by Application USD Million (2022-2027)
  • Table 215. Netherlands RNA Medicine, by End User USD Million (2022-2027)
  • Table 216. Netherlands RNA Medicine, by Technology USD Million (2022-2027)
  • Table 217. Rest of Europe RNA Medicine, by Type USD Million (2022-2027)
  • Table 218. Rest of Europe RNA Medicine, by Application USD Million (2022-2027)
  • Table 219. Rest of Europe RNA Medicine, by End User USD Million (2022-2027)
  • Table 220. Rest of Europe RNA Medicine, by Technology USD Million (2022-2027)
  • Table 221. MEA RNA Medicine, by Country USD Million (2022-2027)
  • Table 222. MEA RNA Medicine, by Type USD Million (2022-2027)
  • Table 223. MEA RNA Medicine, by Application USD Million (2022-2027)
  • Table 224. MEA RNA Medicine, by End User USD Million (2022-2027)
  • Table 225. MEA RNA Medicine, by Technology USD Million (2022-2027)
  • Table 226. Middle East RNA Medicine, by Type USD Million (2022-2027)
  • Table 227. Middle East RNA Medicine, by Application USD Million (2022-2027)
  • Table 228. Middle East RNA Medicine, by End User USD Million (2022-2027)
  • Table 229. Middle East RNA Medicine, by Technology USD Million (2022-2027)
  • Table 230. Africa RNA Medicine, by Type USD Million (2022-2027)
  • Table 231. Africa RNA Medicine, by Application USD Million (2022-2027)
  • Table 232. Africa RNA Medicine, by End User USD Million (2022-2027)
  • Table 233. Africa RNA Medicine, by Technology USD Million (2022-2027)
  • Table 234. North America RNA Medicine, by Country USD Million (2022-2027)
  • Table 235. North America RNA Medicine, by Type USD Million (2022-2027)
  • Table 236. North America RNA Medicine, by Application USD Million (2022-2027)
  • Table 237. North America RNA Medicine, by End User USD Million (2022-2027)
  • Table 238. North America RNA Medicine, by Technology USD Million (2022-2027)
  • Table 239. United States RNA Medicine, by Type USD Million (2022-2027)
  • Table 240. United States RNA Medicine, by Application USD Million (2022-2027)
  • Table 241. United States RNA Medicine, by End User USD Million (2022-2027)
  • Table 242. United States RNA Medicine, by Technology USD Million (2022-2027)
  • Table 243. Canada RNA Medicine, by Type USD Million (2022-2027)
  • Table 244. Canada RNA Medicine, by Application USD Million (2022-2027)
  • Table 245. Canada RNA Medicine, by End User USD Million (2022-2027)
  • Table 246. Canada RNA Medicine, by Technology USD Million (2022-2027)
  • Table 247. Mexico RNA Medicine, by Type USD Million (2022-2027)
  • Table 248. Mexico RNA Medicine, by Application USD Million (2022-2027)
  • Table 249. Mexico RNA Medicine, by End User USD Million (2022-2027)
  • Table 250. Mexico RNA Medicine, by Technology USD Million (2022-2027)
  • Table 251. RNA Medicine: by Type(USD/Units)
  • Table 252. Research Programs/Design for This Report
  • Table 253. Key Data Information from Secondary Sources
  • Table 254. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global RNA Medicine: by Type USD Million (2017-2022)
  • Figure 5. Global RNA Medicine: by Application USD Million (2017-2022)
  • Figure 6. South America RNA Medicine Share (%), by Country
  • Figure 7. Asia Pacific RNA Medicine Share (%), by Country
  • Figure 8. Europe RNA Medicine Share (%), by Country
  • Figure 9. MEA RNA Medicine Share (%), by Country
  • Figure 10. North America RNA Medicine Share (%), by Country
  • Figure 11. Global RNA Medicine: by Type USD/Units (2017-2022)
  • Figure 12. Global RNA Medicine share by Players 2022 (%)
  • Figure 13. Global RNA Medicine share by Players (Top 3) 2022(%)
  • Figure 14. Global RNA Medicine share by Players (Top 5) 2022(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 17. Pfizer (United States) Revenue: by Geography 2022
  • Figure 18. Sarepta Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 19. Sarepta Therapeutics (United States) Revenue: by Geography 2022
  • Figure 20. Quark (United States) Revenue, Net Income and Gross profit
  • Figure 21. Quark (United States) Revenue: by Geography 2022
  • Figure 22. RXi (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 23. RXi (United Kingdom) Revenue: by Geography 2022
  • Figure 24. Senesco (United States) Revenue, Net Income and Gross profit
  • Figure 25. Senesco (United States) Revenue: by Geography 2022
  • Figure 26. Roche (‎Switzerland) Revenue, Net Income and Gross profit
  • Figure 27. Roche (‎Switzerland) Revenue: by Geography 2022
  • Figure 28. Ionis Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 29. Ionis Pharmaceuticals (United States) Revenue: by Geography 2022
  • Figure 30. Moderna (Europe) Revenue, Net Income and Gross profit
  • Figure 31. Moderna (Europe) Revenue: by Geography 2022
  • Figure 32. Sanofi-Aventis (France) Revenue, Net Income and Gross profit
  • Figure 33. Sanofi-Aventis (France) Revenue: by Geography 2022
  • Figure 34. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 35. Abbott Laboratories (United States) Revenue: by Geography 2022
  • Figure 36. BioNTech (Germany) Revenue, Net Income and Gross profit
  • Figure 37. BioNTech (Germany) Revenue: by Geography 2022
  • Figure 38. Tekmira (Canada) Revenue, Net Income and Gross profit
  • Figure 39. Tekmira (Canada) Revenue: by Geography 2022
  • Figure 40. Alnylam Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 41. Alnylam Pharmaceuticals (United States) Revenue: by Geography 2022
  • Figure 42. Arrowhead Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 43. Arrowhead Pharmaceuticals (United States) Revenue: by Geography 2022
  • Figure 44. Benitec Biopharma (United States) Revenue, Net Income and Gross profit
  • Figure 45. Benitec Biopharma (United States) Revenue: by Geography 2022
  • Figure 46. Global RNA Medicine: by Type USD Million (2022-2027)
  • Figure 47. Global RNA Medicine: by Application USD Million (2022-2027)
  • Figure 48. South America RNA Medicine Share (%), by Country
  • Figure 49. Asia Pacific RNA Medicine Share (%), by Country
  • Figure 50. Europe RNA Medicine Share (%), by Country
  • Figure 51. MEA RNA Medicine Share (%), by Country
  • Figure 52. North America RNA Medicine Share (%), by Country
  • Figure 53. Global RNA Medicine: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Pfizer (United States)
  • Sarepta Therapeutics (United States)
  • Quark (United States)
  • RXi (United Kingdom)
  • Senesco (United States)
  • Roche (‎Switzerland)
  • Ionis Pharmaceuticals (United States)
  • Moderna (Europe)
  • Sanofi-Aventis (France)
  • Abbott Laboratories (United States)
  • BioNTech (Germany)
  • Tekmira (Canada)
  • Alnylam Pharmaceuticals (United States)
  • Arrowhead Pharmaceuticals (United States)
  • Benitec Biopharma (United States)
Additional players considered in the study are as follows:
Calimmune Inc (United States) , Dicerna (United States) , Gradalis (United States) , Silence Therapeutics (United Kingdom) , Silenseed (Israel)
Select User Access Type

Key Highlights of Report


Sep 2022 213 Pages 52 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global RNA Medicine Market Quantitative research analysis
Global RNA Medicine Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in RNA Medicine Market are by type [RNA Interference, ASO, miRNA, Nucleic Acid Aptamers and Others], by end use application [Cancer, Diabetes, Genetic Disorder, Cardiovascular Diseases and Others].
The RNA Medicine Market is gaining popularity and expected to see strong valuation by 2027.
  • Increase in chronic diseases and disorders drives the market growth
  • Rise in the geriatric population propels the market forward

Know More About Global RNA Medicine Market Report?

Have a Query? Click Here

Other Related Reports

Pet Animal Health-Products Comprehensive Study by Type (Drug, Vaccine, Feed, Diagnostics, Others), Distribution Channels (Manufacturers, Suppliers, Medical Stores, Online Retailers, Hypermarket/Super...
$ 3800
Bio Mems Microfluidics Comprehensive Study by Type (Biomedical MEMS, Biotechnological MEMS), Application (Capillary Electrophoresis, Isoelectric Focusing, DNA Analysis, Cell Patterning., Other), Mate...
$ 3800
Pancreatic Beta Cell Protection Comprehensive Study by Type (Gene Treatments, RNA-Based Treatments, Herbal therapy, Others), Application (Hospital, Medical Laboratory, Household, Others), End Users (...
$ 3800
Sepsis Biomarkers Comprehensive Study by Test (Blood tests, Confirmatory/Diagnostic Tests, Urine tests), Technology (Microbiology, Molecular Diagnostics, Polymerase Chain Reaction (PCR), DNA Microar...
$ 3800
Clinical Trial Outsourcing and Management Comprehensive Study by Services (Data Management, Site Management, Clinical Supply Management, Record Management, Others), Development (Enterprise-wide CTMS,...
$ 3800
Self service Pharmacies Comprehensive Study by Type (Patient Facing, Professional Data Feeding), Application (Check-Out, Ordering Repeat Prescriptions, Identity Verification, Stock Control), Features...
$ 3800